
Jeffrey S. Parkin
Examiner (ID: 2776)
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1648, 1641, 1813, 1671 |
| Total Applications | 1731 |
| Issued Applications | 935 |
| Pending Applications | 260 |
| Abandoned Applications | 571 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 9294047
[patent_doc_number] => 20140037681
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-02-06
[patent_title] => 'HIV-1 ENVELOPE GLYCOPROTEIN'
[patent_app_type] => utility
[patent_app_number] => 13/928561
[patent_app_country] => US
[patent_app_date] => 2013-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 21927
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13928561
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/928561 | Methods for identifying broadly neutralizing antibodies utilizing recombinant HIV-1 envelope glycoproteins comprising stabilizing mutations | Jun 26, 2013 | Issued |
Array
(
[id] => 9569764
[patent_doc_number] => 20140187476
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-03
[patent_title] => 'PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION'
[patent_app_type] => utility
[patent_app_number] => 13/926698
[patent_app_country] => US
[patent_app_date] => 2013-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 14227
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13926698
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/926698 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION | Jun 24, 2013 | Abandoned |
Array
(
[id] => 11356401
[patent_doc_number] => 09533040
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-01-03
[patent_title] => 'Inhibition of human immunodeficiency virus integrase reaching dimer formation utilizing single-chain variable antibodies'
[patent_app_type] => utility
[patent_app_number] => 13/923494
[patent_app_country] => US
[patent_app_date] => 2013-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 55
[patent_no_of_words] => 30153
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13923494
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/923494 | Inhibition of human immunodeficiency virus integrase reaching dimer formation utilizing single-chain variable antibodies | Jun 20, 2013 | Issued |
Array
(
[id] => 10298835
[patent_doc_number] => 20150183835
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-07-02
[patent_title] => 'STABILIZED GP120'
[patent_app_type] => utility
[patent_app_number] => 14/408466
[patent_app_country] => US
[patent_app_date] => 2013-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 10687
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14408466
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/408466 | STABILIZED GP120 | Jun 16, 2013 | Abandoned |
Array
(
[id] => 10614876
[patent_doc_number] => 09334310
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-05-10
[patent_title] => 'HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies'
[patent_app_type] => utility
[patent_app_number] => 13/914252
[patent_app_country] => US
[patent_app_date] => 2013-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 9
[patent_no_of_words] => 27460
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13914252
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/914252 | HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies | Jun 9, 2013 | Issued |
Array
(
[id] => 10267145
[patent_doc_number] => 20150152140
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-06-04
[patent_title] => 'PEPTIDES DERIVED FROM VIRAL PROTEINS FOR USE AS IMMUNOGENS AND DOSAGE REACTANTS'
[patent_app_type] => utility
[patent_app_number] => 14/406016
[patent_app_country] => US
[patent_app_date] => 2013-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 38845
[patent_no_of_claims] => 101
[patent_no_of_ind_claims] => 78
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14406016
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/406016 | Peptides derived from viral proteins for use as immunogens and dosage reactants | Jun 5, 2013 | Issued |
Array
(
[id] => 10247259
[patent_doc_number] => 20150132255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-05-14
[patent_title] => 'HIV VACCINE'
[patent_app_type] => utility
[patent_app_number] => 14/405302
[patent_app_country] => US
[patent_app_date] => 2013-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 36740
[patent_no_of_claims] => 46
[patent_no_of_ind_claims] => 21
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14405302
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/405302 | Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer | Jun 5, 2013 | Issued |
Array
(
[id] => 10289237
[patent_doc_number] => 20150174235
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-06-25
[patent_title] => 'VACCINE'
[patent_app_type] => utility
[patent_app_number] => 14/405093
[patent_app_country] => US
[patent_app_date] => 2013-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30202
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 35
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14405093
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/405093 | VACCINE | Jun 5, 2013 | Abandoned |
Array
(
[id] => 14980675
[patent_doc_number] => 10444245
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-10-15
[patent_title] => Trapping mammalian protein-protein complexes in virus-like particles utilizing HIV-1 GAG-bait fusion proteins
[patent_app_type] => utility
[patent_app_number] => 14/402667
[patent_app_country] => US
[patent_app_date] => 2013-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 9868
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14402667
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/402667 | Trapping mammalian protein-protein complexes in virus-like particles utilizing HIV-1 GAG-bait fusion proteins | May 23, 2013 | Issued |
Array
(
[id] => 9330571
[patent_doc_number] => 20140057354
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-02-27
[patent_title] => 'ANTIGEN-SPECIFIC REGULATORY T-CELL INDUCTION'
[patent_app_type] => utility
[patent_app_number] => 13/898565
[patent_app_country] => US
[patent_app_date] => 2013-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 11860
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13898565
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/898565 | ANTIGEN-SPECIFIC REGULATORY T-CELL INDUCTION | May 20, 2013 | Abandoned |
Array
(
[id] => 9989436
[patent_doc_number] => 09034638
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-05-19
[patent_title] => 'Arrayed detector system for measurement of anti-viral immune response'
[patent_app_type] => utility
[patent_app_number] => 13/898143
[patent_app_country] => US
[patent_app_date] => 2013-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 9
[patent_no_of_words] => 9334
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13898143
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/898143 | Arrayed detector system for measurement of anti-viral immune response | May 19, 2013 | Issued |
Array
(
[id] => 11283745
[patent_doc_number] => 09499589
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-11-22
[patent_title] => 'Chimeric vaccines'
[patent_app_type] => utility
[patent_app_number] => 13/897319
[patent_app_country] => US
[patent_app_date] => 2013-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 26
[patent_no_of_words] => 29334
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13897319
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/897319 | Chimeric vaccines | May 16, 2013 | Issued |
Array
(
[id] => 9586728
[patent_doc_number] => RE045016
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2014-07-15
[patent_title] => 'Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses'
[patent_app_type] => reissue
[patent_app_number] => 13/896396
[patent_app_country] => US
[patent_app_date] => 2013-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 47499
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13896396
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/896396 | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses | May 16, 2013 | Issued |
Array
(
[id] => 9619053
[patent_doc_number] => RE045053
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2014-07-29
[patent_title] => 'Attenuated dengue virus comprising mutations in the NS3 gene'
[patent_app_type] => reissue
[patent_app_number] => 13/896411
[patent_app_country] => US
[patent_app_date] => 2013-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 14
[patent_no_of_words] => 53209
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13896411
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/896411 | Attenuated dengue virus comprising mutations in the NS3 gene | May 16, 2013 | Issued |
Array
(
[id] => 9701404
[patent_doc_number] => RE045123
[patent_country] => US
[patent_kind] => E1
[patent_issue_date] => 2014-09-09
[patent_title] => 'Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis'
[patent_app_type] => reissue
[patent_app_number] => 13/896409
[patent_app_country] => US
[patent_app_date] => 2013-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 14
[patent_no_of_words] => 47071
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13896409
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/896409 | Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis | May 16, 2013 | Issued |
| 13/867957 | METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS | Apr 21, 2013 | Abandoned |
Array
(
[id] => 9916750
[patent_doc_number] => 20150071954
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-03-12
[patent_title] => 'STABLE PEPTIDE MIMETICS OF THE HIV-1 GP41 PRE-HAIRPIN INTERMEDIATE'
[patent_app_type] => utility
[patent_app_number] => 14/386514
[patent_app_country] => US
[patent_app_date] => 2013-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 24329
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386514
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/386514 | STABLE PEPTIDE MIMETICS OF THE HIV-1 GP41 PRE-HAIRPIN INTERMEDIATE | Mar 14, 2013 | Abandoned |
Array
(
[id] => 12043466
[patent_doc_number] => 09821050
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-11-21
[patent_title] => 'Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions'
[patent_app_type] => utility
[patent_app_number] => 14/390312
[patent_app_country] => US
[patent_app_date] => 2013-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 11
[patent_no_of_words] => 20482
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 253
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14390312
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/390312 | Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions | Mar 14, 2013 | Issued |
Array
(
[id] => 9864119
[patent_doc_number] => 20150044137
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-02-12
[patent_title] => 'NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE'
[patent_app_type] => utility
[patent_app_number] => 14/386920
[patent_app_country] => US
[patent_app_date] => 2013-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 57
[patent_figures_cnt] => 57
[patent_no_of_words] => 35961
[patent_no_of_claims] => 46
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386920
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/386920 | NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE | Mar 14, 2013 | Abandoned |
Array
(
[id] => 9054012
[patent_doc_number] => 20130251726
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-09-26
[patent_title] => 'NOVEL HIV -1 BROADLY NEUTRALIZING ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 13/792098
[patent_app_country] => US
[patent_app_date] => 2013-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 49
[patent_figures_cnt] => 49
[patent_no_of_words] => 35566
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13792098
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/792098 | HIV-1 broadly neutralizing antibodies | Mar 9, 2013 | Issued |